ADMA - ADMAバイオロジックス (ADMA Biologics Inc) ADMAバイオロジックス

 ADMAのチャート


 ADMAの企業情報

symbol ADMA
会社名 ADMA Biologics Inc (ADMAバイオロジックス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ADMA Biologics Inc. is a late-stage biopharmaceutical company that develops manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers which includes its operations in Georgia; Research and Development which includes its plasma development operations in New Jersey and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate RI-002 is intended for the treatment of primary immune deficiency disease.   ADMA バイオロジックスは、米国のバイオ医薬品企業。特定の感染症の治療および予防のためのプラズマベ―スの生物製剤の開発、製造、売買に従事する。同社が焦点を当てる患者集団は、基礎免疫不全障害に苦しむ免疫無防備状態の患者が含まれる。主な製品候補「RI-002」は、原発性免疫不全症の治療のために投与される。   
本社所在地 465 State Route 17 Ramsey NJ 07446 USA
代表者氏名 Steven A. Elms スティーブンA.エルムズ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 201-478-5552
設立年月日 38139
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 295人
url www.admabiologics.com
nasdaq_url https://www.nasdaq.com/symbol/adma
adr_tso
EBITDA EBITDA(百万ドル) -50.10306
終値(lastsale) 5.78
時価総額(marketcap) 267900190.92
時価総額 時価総額(百万ドル) 275.31610
売上高 売上高(百万ドル) 25.43085
企業価値(EV) 企業価値(EV)(百万ドル) 263.82142
当期純利益 当期純利益(百万ドル) -60.75549
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 ADMA Biologics Inc revenues increased 44% to $8.7M. Net loss increased from $15.6M to $32.6M. Revenues reflect ADMA Bio Manufacturing segment increase from $539K to $3.8M Corporate segment remaining flat at $71K. Higher net loss reflects ADMA Bio Manufacturing segment loss increase from $3.1M to $22.6M Plasma Collection Center segment loss increase of 78% to $2M.

 ADMAのテクニカル分析


 ADMAのニュース

   Stock market news live updates: Stock futures rise as lawmakers draw closer to stimulus agreement – Yahoo Finance | Elite Investor  2020/12/09 03:12:25 Elite Investor
On Wall Street, it’s out with tech and mega-caps and in with small-caps, cyclicals and value. Investors have been rotating away from the big names that powered the market’s record-breaking charge forward since its March low on encouraging COVID-19 vaccine news. At the same time, there has been a weaker U.S. dollar, steeper yield curve and a commodity price run-up.What does all of this mean? According to Raymond James strategist Tavis McCourt, it is “indicative of investor belief in strong economic growth in 2021, driven by economic re-opening and a ‘wall of cash’ sitting in bank accounts that will be deployed into the real economy in 2021.” The strategist adds that investor focus has landed squarely on a new stimulus package, which “only increases the chances for robust growth in 2021 as economies fully re-open.”“This outweighed significant evidence of slowing economic trends (jobs growth, Visa credit/debit card spending, Bloomberg high frequency data), which the market broadly is viewing as a short-term phenomenon until vaccines are deployed, as PMs continue to reposition portfolios in preparation for economic re-openings,” McCourt explained.Taking McCourt’s outlook into consideration, we wanted to take a closer look at two penny stocks scoring rave reviews from Raymond James.
   ADMA Biologics (NASDAQ:ADMA) Stock Price Up 6%  2020/10/22 19:37:04 US Banking News
Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) rose 6% during mid-day trading on Thursday . The company traded as high as $2.34 and last traded at $2.29. Approximately 2,679,344 shares changed hands during trading, a decline of 28% from the average daily volume of 3,737,513 shares. The stock had previously closed at $2.16. ADMA has been […]
   Insider Buys ADMA Biologics Stock  2020/09/14 11:56:00 Benzinga
A Form 4 filing filed with the SEC on Monday, September 14 showed that Demski Martha J bought 2,200 shares of ADMA Biologics Inc (NASDAQ:ADMA) at an average …
   Thinking about buying stock in UnitedHealth, VBI Vaccines Inc, ADMA Biologics, Qutoutiao, or Lipocine Inc?  2020/08/28 13:31:00 PR Newswire
NEW YORK, Aug. 28, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for UNH, VBIV, ADMA, QTT, and LPCN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   These Plasma Stocks Are Surging After FDA's Convalescent EUA  2020/08/24 13:34:33 Benzinga
Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use of investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients. The EUA, according to the FDA, will allow the distribution of COVID-19 convalescent plasma in the U.S. and its administration by health care providers. "This is a powerful therapy that transfuses very, very strong antibodies from the blood of recovered patients to help treat patients battling a current infection. It's had an incredible rate of success," President Trump said in his Aug. 23 press briefing. "Today's action will dramatically expand access to this treatment." Although opinions are divided about the effectiveness of the therapy, given views among some quarters that the FDA had buckled under political pressure in according authorization, the following stocks are skyrocketing on the announcement.
   Stock market news live updates: Stock futures rise as lawmakers draw closer to stimulus agreement – Yahoo Finance | Elite Investor  2020/12/09 03:12:25 Elite Investor
On Wall Street, it’s out with tech and mega-caps and in with small-caps, cyclicals and value. Investors have been rotating away from the big names that powered the market’s record-breaking charge forward since its March low on encouraging COVID-19 vaccine news. At the same time, there has been a weaker U.S. dollar, steeper yield curve and a commodity price run-up.What does all of this mean? According to Raymond James strategist Tavis McCourt, it is “indicative of investor belief in strong economic growth in 2021, driven by economic re-opening and a ‘wall of cash’ sitting in bank accounts that will be deployed into the real economy in 2021.” The strategist adds that investor focus has landed squarely on a new stimulus package, which “only increases the chances for robust growth in 2021 as economies fully re-open.”“This outweighed significant evidence of slowing economic trends (jobs growth, Visa credit/debit card spending, Bloomberg high frequency data), which the market broadly is viewing as a short-term phenomenon until vaccines are deployed, as PMs continue to reposition portfolios in preparation for economic re-openings,” McCourt explained.Taking McCourt’s outlook into consideration, we wanted to take a closer look at two penny stocks scoring rave reviews from Raymond James.
   ADMA Biologics (NASDAQ:ADMA) Stock Price Up 6%  2020/10/22 19:37:04 US Banking News
Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) rose 6% during mid-day trading on Thursday . The company traded as high as $2.34 and last traded at $2.29. Approximately 2,679,344 shares changed hands during trading, a decline of 28% from the average daily volume of 3,737,513 shares. The stock had previously closed at $2.16. ADMA has been […]
   Insider Buys ADMA Biologics Stock  2020/09/14 11:56:00 Benzinga
A Form 4 filing filed with the SEC on Monday, September 14 showed that Demski Martha J bought 2,200 shares of ADMA Biologics Inc (NASDAQ:ADMA) at an average …
   Thinking about buying stock in UnitedHealth, VBI Vaccines Inc, ADMA Biologics, Qutoutiao, or Lipocine Inc?  2020/08/28 13:31:00 PR Newswire
NEW YORK, Aug. 28, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for UNH, VBIV, ADMA, QTT, and LPCN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   These Plasma Stocks Are Surging After FDA's Convalescent EUA  2020/08/24 13:34:33 Benzinga
Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use of investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients. The EUA, according to the FDA, will allow the distribution of COVID-19 convalescent plasma in the U.S. and its administration by health care providers. "This is a powerful therapy that transfuses very, very strong antibodies from the blood of recovered patients to help treat patients battling a current infection. It's had an incredible rate of success," President Trump said in his Aug. 23 press briefing. "Today's action will dramatically expand access to this treatment." Although opinions are divided about the effectiveness of the therapy, given views among some quarters that the FDA had buckled under political pressure in according authorization, the following stocks are skyrocketing on the announcement.
   10 drugmakers are working together to develop a treatment based on the blood of COVID-19 survivors, and they plan to start testing in humans next month  2020/06/14 13:05:00 Business Insider
Potential coronavirus vaccines take a long time to develop. In the meantime, the hunt for COVID-19 treatments is fully underway. 10 biopharma companies — including Takeda, Japan's largest drugmaker — are collaborating to advance one plasma-based therapy. The companies hope to start human testing in July, finish the trial by the fall, and gain approval by year's end. If it works, the treatment may help combat a second wave of the virus. The coalition is now seeking volunteers who have recovered from COVID-19 to donate plasma. For more stories like this, sign up here for our healthcare newsletter Dispensed . A coalition of 10 biopharma companies are aiming to have a plasma-based COVID-19 therapy ready in time for a potential second wave of the coronavirus later this year. The experimental treatment is called a hyperimmune globulin, a more standardized form of a traditional convalescent plasma transfusion. The drug is made from the antibody-rich blood of coronavirus surivivors. The companies hope this will help ill patients fight the virus and recover with a boosted immune response.
   Are Options Traders Betting on a Big Move in ADMA Biologics (ADMA) Stock?  2020/06/01 13:44:00 Zacks Investment Research
Investors need to pay close attention to ADMA Biologics (ADMA) stock based on the movements in the options market lately.
   Adma Biologics (ADMA) Reports Q1 Loss, Misses Revenue Estimates  2020/05/07 00:15:05 Zacks Investment Research
Adma Biologics (ADMA) delivered earnings and revenue surprises of -100.00% and -4.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection  2020/03/19 11:37:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ: BMRA )( announced commencement of international shipment of rapid COVID-19 test) BioNTech SE – ADR (NASDAQ: BNTX ) Imara Inc (NASDAQ: IMRA ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 18) 89bio Inc (NASDAQ: ETNB ) AC Immune SA (NASDAQ: ACIU ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) ADMA Biologics Inc (NASDAQ: ADMA ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agenus Inc (NASDAQ: AGEN ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Aikido Pharma Inc (NASDAQ: AIKI ) Akorn, Inc. (NASDAQ: AKRX ) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Alterity Therapeutics Ltd (NASDAQ: ATHE ) AMAG Pharmaceuticals, Inc.
   The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings  2020/03/13 11:52:53 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo Corporation (NASDAQ: MASI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ADMAバイオロジックス ADMA ADMA Biologics Inc)

 twitter  (公式ツイッターやCEOツイッターなど)